The Discounted Cash Flow (DCF) valuation of Alnylam Pharmaceuticals Inc (ALNY) is (205.12) USD. With the latest stock price at 245.44 USD, the upside of Alnylam Pharmaceuticals Inc based on DCF is -183.6%.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| WACC / Discount Rate | 8.0% - 10.3% | 9.1% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | (342.86) - (148.40) | (205.12) |
| Upside | -239.7% - -160.5% | -183.6% |